Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
FOENIX-CCA2
A Study of TAS-120 in Patients With Advanced Solid Tumors
- NCT02052778 ↗
- Completed
- Taiho Oncology, Inc.
- Deep
We haven't built an HCP commentary report on FOENIX-CCA2 (futibatinib in Cholangiocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on FOENIX-CCA2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 14 | |
| YouTube | 10 | |
| Podcasts | 9 |
The trial
ClinicalTrials.gov- Official title
- Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Cholangiocarcinoma; Urothelial Cancer; Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors; Primary CNS Tumors; Breast Cancer; Gastric Cancer
- Interventions
- Futibatinib
- Arms
- Phase 1: Dose Escalation: QOD Dosing: 8 mg · Experimental
- Phase 1: Dose Escalation: QOD Dosing: 16 mg · Experimental
- Phase 1: Dose Escalation: QOD Dosing: 24 mg · Experimental
- Phase 1: Dose Escalation: QOD Dosing: 36 mg · Experimental
- Phase 1: Dose Escalation: QOD Dosing: 56 mg · Experimental
- Phase 1: Dose Escalation: QOD Dosing: 80 mg · Experimental
- Phase 1: Dose Escalation: QOD Dosing: 120 mg · Experimental
- Phase 1: Dose Escalation: QOD Dosing: 160 mg · Experimental
- Phase 1: Dose Escalation: QOD Dosing: 200 mg · Experimental
- Phase 1: Dose Escalation: QD Dosing: 4 mg · Experimental
- Phase 1: Dose Escalation: QD Dosing: 8 mg · Experimental
- Phase 1: Dose Escalation: QD Dosing: 16 mg · Experimental
- Phase 1: Dose Escalation: QD Dosing: 20 mg · Experimental
- Phase 1: Dose Escalation: QD Dosing: 24 mg · Experimental
- Phase 1: Dose Expansion Cohort 1 · Experimental
- Phase 1: Dose Expansion: Cohort 2 · Experimental
- Phase 1: Dose Expansion: Cohort 3 · Experimental
- Phase 1: Dose Expansion: Cohort 4 · Experimental
- Phase 1:Dose Expansion: Cohort 5 · Experimental
- Phase 1: Dose Expansion: Cohort 6 · Experimental
- Phase 1: Dose Expansion: Sub-cohort 1 · Experimental
- Phase 1: Dose Expansion: Sub-cohort 2 · Experimental
- Phase 2 · Experimental
- Enrollment
- 407
- Primary outcomes
- Phase 1: Dose Escalation-Maximum Tolerated Dose (MTD)
- Phase 1: Dose Escalation-Recommended Phase 2 Dose (RP2D) of TAS-120
- Phase 1: Dose Expansion: Percentage of Participants With Objective Response
- Phase 2: Percentage of Participants With Objective Response
- Sponsor
- Taiho Oncology, Inc.
- Start
- Jul 21, 2014
- Primary completion
- Oct 1, 2020
- Results posted
- Yes
- Registry record
- NCT02052778 · updated Mar 27, 2025
Publications
linked from the registry- Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klumpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Komatsu Y, Ahn DH, Epstein RS, Halim AB, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA; FOENIX-CCA2 Study Investigators. Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer. Future Oncol. 2024;20(36):2811-2822. doi: 10.1080/14796694.2024.2364504. Epub 2024 Jun 17. PubMed 38884254
- DiPeri TP, Zhao M, Evans KW, Varadarajan K, Moss T, Scott S, Kahle MP, Byrnes CC, Chen H, Lee SS, Halim AB, Hirai H, Wacheck V, Kwong LN, Rodon J, Javle M, Meric-Bernstam F. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. 2024 Feb;80(2):322-334. doi: 10.1016/j.jhep.2023.10.041. Epub 2023 Nov 14. PubMed 37972659
- Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klumpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Mitchell EP, Komatsu Y, Masuda K, Ahn D, Epstein RS, Halim AB, Fu Y, Salimi T, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA; FOENIX-CCA2 Study Investigators. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834. PubMed 36652354
- Bahleda R, Meric-Bernstam F, Goyal L, Tran B, He Y, Yamamiya I, Benhadji KA, Matos I, Arkenau HT. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Ann Oncol. 2020 Oct;31(10):1405-1412. doi: 10.1016/j.annonc.2020.06.018. Epub 2020 Jul 2. PubMed 32622884